Complications of subspecialty ophthalmic care: Systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway

David J. Ramsey, Luis Haddock, Lucy H. Young, Dean Eliott

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The treatment of neovascular age-related macular degeneration (AMD) and other pathologic ocular conditions that overexpress the vascular endothelial growth factor (VEGF) has been revolutionized in the last decade by the introduction of intravitreal agents that target the VEGF pathway. Since treatment trials are designed primarily to assess the prevention of vision loss caused by ocular conditions, they are inadequate for detecting rare, but potentially serious, systemic side effects. The aim of this article is to present what the ophthalmologist needs to know about systemic complications from anti-VEGF therapy and review the likelihood that these side effects occur in the context of small, but often-repeated, intravitreal doses of these potent biological medications. Preferred practice patterns need to be developed that weigh the ability of these medications to mitigate potentially blinding conditions, while at the same time minimizing the risk of adverse outcomes in specific patient populations that possess multiple and often interrelated medical comorbidities.

Original languageEnglish (US)
Pages (from-to)263-275
Number of pages13
JournalSeminars in Ophthalmology
Volume29
Issue number5-6
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Aptitude
Macular Degeneration
Comorbidity
Therapeutics
Population
Ophthalmologists

Keywords

  • Angiogenesis
  • Choroidal neovascularization
  • Intravitreal injection
  • Systemic side effects
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Cite this

Complications of subspecialty ophthalmic care : Systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway. / Ramsey, David J.; Haddock, Luis; Young, Lucy H.; Eliott, Dean.

In: Seminars in Ophthalmology, Vol. 29, No. 5-6, 01.09.2014, p. 263-275.

Research output: Contribution to journalArticle

@article{e22191a458b64446910763205eed6dbd,
title = "Complications of subspecialty ophthalmic care: Systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway",
abstract = "The treatment of neovascular age-related macular degeneration (AMD) and other pathologic ocular conditions that overexpress the vascular endothelial growth factor (VEGF) has been revolutionized in the last decade by the introduction of intravitreal agents that target the VEGF pathway. Since treatment trials are designed primarily to assess the prevention of vision loss caused by ocular conditions, they are inadequate for detecting rare, but potentially serious, systemic side effects. The aim of this article is to present what the ophthalmologist needs to know about systemic complications from anti-VEGF therapy and review the likelihood that these side effects occur in the context of small, but often-repeated, intravitreal doses of these potent biological medications. Preferred practice patterns need to be developed that weigh the ability of these medications to mitigate potentially blinding conditions, while at the same time minimizing the risk of adverse outcomes in specific patient populations that possess multiple and often interrelated medical comorbidities.",
keywords = "Angiogenesis, Choroidal neovascularization, Intravitreal injection, Systemic side effects, Vascular endothelial growth factor",
author = "Ramsey, {David J.} and Luis Haddock and Young, {Lucy H.} and Dean Eliott",
year = "2014",
month = "9",
day = "1",
doi = "10.3109/08820538.2014.959195",
language = "English (US)",
volume = "29",
pages = "263--275",
journal = "Seminars in Ophthalmology",
issn = "0882-0538",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - Complications of subspecialty ophthalmic care

T2 - Systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway

AU - Ramsey, David J.

AU - Haddock, Luis

AU - Young, Lucy H.

AU - Eliott, Dean

PY - 2014/9/1

Y1 - 2014/9/1

N2 - The treatment of neovascular age-related macular degeneration (AMD) and other pathologic ocular conditions that overexpress the vascular endothelial growth factor (VEGF) has been revolutionized in the last decade by the introduction of intravitreal agents that target the VEGF pathway. Since treatment trials are designed primarily to assess the prevention of vision loss caused by ocular conditions, they are inadequate for detecting rare, but potentially serious, systemic side effects. The aim of this article is to present what the ophthalmologist needs to know about systemic complications from anti-VEGF therapy and review the likelihood that these side effects occur in the context of small, but often-repeated, intravitreal doses of these potent biological medications. Preferred practice patterns need to be developed that weigh the ability of these medications to mitigate potentially blinding conditions, while at the same time minimizing the risk of adverse outcomes in specific patient populations that possess multiple and often interrelated medical comorbidities.

AB - The treatment of neovascular age-related macular degeneration (AMD) and other pathologic ocular conditions that overexpress the vascular endothelial growth factor (VEGF) has been revolutionized in the last decade by the introduction of intravitreal agents that target the VEGF pathway. Since treatment trials are designed primarily to assess the prevention of vision loss caused by ocular conditions, they are inadequate for detecting rare, but potentially serious, systemic side effects. The aim of this article is to present what the ophthalmologist needs to know about systemic complications from anti-VEGF therapy and review the likelihood that these side effects occur in the context of small, but often-repeated, intravitreal doses of these potent biological medications. Preferred practice patterns need to be developed that weigh the ability of these medications to mitigate potentially blinding conditions, while at the same time minimizing the risk of adverse outcomes in specific patient populations that possess multiple and often interrelated medical comorbidities.

KW - Angiogenesis

KW - Choroidal neovascularization

KW - Intravitreal injection

KW - Systemic side effects

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84912012478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912012478&partnerID=8YFLogxK

U2 - 10.3109/08820538.2014.959195

DO - 10.3109/08820538.2014.959195

M3 - Article

C2 - 25325852

AN - SCOPUS:84912012478

VL - 29

SP - 263

EP - 275

JO - Seminars in Ophthalmology

JF - Seminars in Ophthalmology

SN - 0882-0538

IS - 5-6

ER -